Relationship between the expression of long non-coding RNA OSTN-AS1 and microRNA-1207-3p in prostate cancer tissues and clinicopathological parameters and prognosis
LI Xuyu ZHANG Yu ZHANG Haijian HAN Zhixing JI Shiqi LIU Qingjun
Department of Urology Surgery, Beijing Ditan Hospital Capital Medical University, Beijing 100015, China
Abstract：Objective To investigate the expression of long non-coding RNA (lncRNA) OSTN-AS1 and microrNA (miR) - 1207-3p in prostate cancer (PCa) tissues and their relationship with clinicopathological parameters and prognosis. Methods A total of 102 PCa patients admitted to Beijing Ditan Hospital Capital Medical University from January 2015 to December 2017 were selected. Real-time fluorescence quantitative PCR was used to detect the expression of lncRNA OSTN-AS1 and miR-1207-3p in cancer tissues and adjacent tissues, and the relationship between the expression and clinicopathological characteristics was analyzed. According to the mean expression of lncRNA OSTN-AS1 and miR-1207-3p in cancer tissues, patients were divided into low lncRNA OSTN-AS1 expression group (＜3.26, 50 cases) and high lncRNA OSTN-AS1 expression group (≥3.26, 52 cases); and low miR-1207-3p expression group (＜3.69, 49 cases) and high miR-1207-3p expression group (≥3.69, 53 cases). Follow-up for five years was conducted to analyze the relationship between lncRNA OSTN-AS1, miR-1207-3p, and prognosis. Cox regression analysis of the factors affecting the prognosis of PCa patients. Results The expressions of lncRNA OSTN-AS1 and miR- 1207-3p in PCa tissues were higher than those in paracancer tissues, and the differences were statistically significant (P＜0.05). The expression levels of lncRNA OSTN-AS1 and miR-1207-3p in PCa tissues with different TNM stages, Gleason score and lymph node metastasis were statistically significant (P＜0.05). The 5-year cumulative survival rate of lncRNA OSTN-AS1 high expression group was lower than that of lncRNA OSTN-AS1 low expression group (P＜0.05). The 5-year cumulative survival rate of miR-1207-3p high expression group was lower than that of miR-1207-3p low expression group (P＜0.05). Cox regression analysis showed that TNM stage Ⅲ, Gleason score ＞ seven points, lymph node metastasis, lncRNA OSTN-AS1 high expression, and miR-1207-3p high expression were independent risk factors for the prognosis of PCa patients (P＜0.05). Conclusion The expression of lncRNA OSTN-AS1 and miR-1207-3p increased in PCa tissues, which were related to Gleason score, TNM stage, lymph node metastasis, and prognosis survival, and involved in tumor progression in PCa.
李旭瑜 张玉 张海建 韩志兴 纪世琪 刘庆军. 前列腺癌组织中长链非编码RNA OSTN-AS1、微RNA-1207-3p的表达与临床病理参数和预后的关系[J]. 中国医药导报, 2023, 20(29): 107-111.
LI Xuyu ZHANG Yu ZHANG Haijian HAN Zhixing JI Shiqi LIU Qingjun. Relationship between the expression of long non-coding RNA OSTN-AS1 and microRNA-1207-3p in prostate cancer tissues and clinicopathological parameters and prognosis. 中国医药导报, 2023, 20(29): 107-111.
[1] Rebello RJ，Oing C，Knudsen KE，et al. Prostate cancer [J]. Nat Rev Dis Primers，2021，7（1）：8-15. [2] 张烨，王磊，张璐，等.雄激素受体剪接变异体7在去势抵抗性前列腺癌中的作用及其临床意义[J].中国医药导报，2020，17（1）：46-49. [3] Yan H，Bu P. Non-coding RNA in cancer [J]. Essays Biochem，2021，65（4）：625-639. [4] Liu Z，Mi M，Li X，et al. lncRNA OSTN-AS1 May Represent a Novel Immune-Related Prognostic Marker for Triple-Negative Breast Cancer Based on Integrated Analysis of a ceRNA Network [J]. Front Genet，2019，10（7）：850-859. [5] Wang X，Li L，Xiao W，et al. Plasma microRNA-1207-5p as a Potential Biomarker for Diagnosis and Prognosis of Colorectal Cancer [J]. Clin Lab，2020，66（9）：236-241. [6] Zhang Q，Zheng J，Liu L. Down-regulation of lncRNA LUADT1 suppresses cervical cancer cell growth by sequestering microRNA-1207-5p [J]. Acta Biochim Biophys Sin （Shanghai），2022，54（3）：321-331. [7] 李星，曾晓勇.中国前列腺癌流行病学研究进展[J].肿瘤防治研究，2021，48（1）：98-102. [8] 彭妙官，张莹.前列腺癌低氧相关基因预后风险模型的建立与分析[J].热带医学杂志，2022，22（4）：544-548. [9] 温健男，程超，章泽宇，等.血清前列腺特异性抗原联合Gleason评分对初诊前列腺癌转移风险的预测价值[J].第二军医大学学报，2021，42（4）：371-376. [10] 李娜，左树森，乔玉华.血清PSA、TGF-β1、uPAR、AMACR和尿肌氨酸在前列腺癌诊断中的效能分析[J].山东医药，2023，63（5）：71-74. [11] Wen S，Wei Y，Zen C，et al. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6- methyladenosine [J]. Mol Cancer，2020，19（1）：171-179. [12] Mugoni V，Ciani Y，Nardella C，et al. Circulating RNAs in prostate cancer patients [J]. Cancer Lett，2022，524（7）：57-69. [13] Ding L，Wang R，Shen D，et al. Role of noncoding RNA in drug resistance of prostate cancer [J]. Cell Death Dis，2021， 12（6）：590-599. [14] 田莉，赵济华，徐晋珩，等.lncRNA OSTN-AS1下调miR- 4461表达促进前列腺癌LNCaP细胞增殖、迁移和侵袭[J].医学分子生物学杂志，2023，20（3）：215-220. [15] 崔海军，田莉，赵济华，等.lncRNA OSTN-AS1通过靶向调控miR-330-5p表达对前列腺癌DU145细胞增殖、迁移及侵袭的影响[J].中国男科学杂志，2022，36（4）：62-67. [16] Jiang T，Guo J，Hu Z，et al. Identification of Potential Prostate Cancer-Related Pseudogenes Based on Competitive Endogenous RNA Network Hypothesis [J]. Med Sci Monit，2018， 24（9）：4213-4239. [17] Zang Y，Zhu J，Li Q，et al. miR-137-3p Modulates the Progression of Prostate Cancer by Regulating the JNK3/ EZH2 Axis [J]. Onco Targets Ther，2020，13（5）：7921-7932. [18] Diener C，Keller A，Meese E. Emerging concepts of miRNA therapeutics：from cells to clinic [J]. Trends Genet，2022，38（6）：613-626. [19] Coradduzza D，Cruciani S，Arru C，et al. Role of miRNA- 145，148，and 185 and Stem Cells in Prostate Cancer [J]. Int J Mol Sci，2022，23（3）：1626. [20] Chakraborty S，Nath D. A Study on microRNAs Targeting the Genes Overexpressed in Lung Cancer and their Codon Usage Patterns [J]. Mol Biotechnol，2022，64（10）：1095-1119. [21] Liu X，Zeng Y，Liu Z，et al. Bioinformatics analysis of the circRNA-miRNA-mRNA network for atrial fibrillation [J]. Medicine （Baltimore），2022，101（34）：e30221. [22] Das DK，Osborne JR，Lin HY，et al. miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer [J]. Transl Oncol，2016，9（3）：236-241. [23] Das DK，Naidoo M，Ilboudo A，et al. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin [J]. Exp Cell Res，2016，348（2）：190-200. [24] Bi Y，Ji J，Zhou Y. LncRNA-PVT1 indicates a poor prognosis and promotes angiogenesis via activating the HNF1B/ EMT axis in glioma [J]. J Cancer，2021，12（19）：5732-5744. [25] You L，Wang H，Yang G，et al. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207 [J]. Mol Oncol，2018， 12（12）：2147-2164.
2023, Vol. 20 
京公网安备 11010502046598号